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ABSTRACT 
Metformin has been used clinically since 1957 for its efficacy and safety as 
therapy for type 2 diabetes. Besides ameliorating hyperglycemia without risk of 
hypoglycemia, metformin also lowers plasma triglyceride levels. Furthermore, a wealth 
of data shows that metformin facilitates weight loss in mice as well as humans. Due to its 
numerous metabolic benefits, researchers and clinicians are interested in the possibility of 
using metformin as treatment to combat obesity and other metabolic disorders such as 
non-alcoholic fatty liver disease (NAFLD). Despite being the most commonly prescribed 
anti-diabetic, metformin’s complete mechanism(s) for weight loss or for lowering 
glucose and lipids remains an enigma. Our studies show that metformin-treated mice 
exhibited decreased caloric intake, providing a viable mechanism for metformin to bring 
about weight loss. Intriguingly, we found that metformin induces PRDM16 to promote 
browning of iWAT and increase expression of thermogenic genes such as UCP1 and 
DIO2. However, metformin did not appear to increase energy expenditure. It’s possible 
that metformin’s effect on energy expenditure was masked since energy expenditure 
	  	   vii	  
measurements were taken when metformin-treated mice were still losing weight and were 
in a state of negative energy balance. 
Recently, there has been much attention given to AMPK activators as exercise 
mimetics. Metformin is known to activate AMPK and similarly brings about many 
beneficial effects as exercise such as alleviation of obesity-induced NAFLD. SIRT1 
stimulation by resveratrol and delivery of exogenous FGF21 mimics metformin’s ability 
to combat obesity and improve NAFLD. Collectively, these results implicate metformin, 
resveratrol, and exogenous administration of FGF21 as beneficial therapies for weight 
loss and amelioration of NAFLD.
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INTRODUCTION 
 
Nutrients are required to maintain energy homeostasis and sustain life. The ability 
to adapt and respond to various nutrient fluxes is an ancient cellular function—an ability 
conserved from unicellular to complex multicellular organisms, including mammals. At 
the central level, the hypothalamus is the primary component of the nervous system that 
interprets nutrient-related inputs. The hypothalamus then delivers hormonal and 
behavioral responses with the goal of regulating energy intake and energy consumption. 
At the molecular level, molecules or enzymes, referred to as nutrient/energy sensors, 
mediate metabolic responses of specific tissues involved in energy balance (Toorie and 
Nillni, 2014). The regulation and function of nutrient sensing pathways are vital because 
the organism must maintain energy homeostasis even if the nutritional status of the 
organism fluctuates between positive energy balance (overnutrition) and negative energy 
balance (fasting or prolonged caloric restriction). To maintain energy homeostasis, 
mammals adapt to changes in nutritional status through modulation of tissue-specific 
metabolic pathways via nutrient sensors (Fulco, 2008). 
General Roles of the Nutrient Sensors—AMPK, SIRT1, and FGF21 
AMP-activated protein kinase (AMPK) 
Nutrient sensors such as AMPK, SIRT1, and FGF21 play a major role in 
maintaining energy homeostasis by assessing nutritional status and appropriately 
regulating metabolic responses. AMPK is an energy-sensing protein kinase that is highly 
conserved and regulates cellular metabolism. It is a heterotrimeric protein kinase 
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consisting of a catalytic α subunit and regulatory β and γ subunits. Each subunit has 
multiple isoforms (α1, α2, β1, β2, γ1, γ2, γ3), but the predominant isoforms in the liver 
are AMPKα1, β1, γ1, which account for over 90% of AMPK activity in hepatocytes. 
Critical for the activation of this enzyme, its upstream kinases such as LKB1 and 
CaMKKβ phosphorylate AMPKα subunits at Thr-172 (Kahn et al., 2005). In contrast, 
phosphorylation of the α subunits at Ser-485/497 by PKA reduces α subunit 
phosphorylation at Thr-172, thus decreasing AMPK enzyme activity (Xiao et al., 2007). 
When cellular energy levels are low, the increase in the AMP/ATP or ADP/ATP 
ratio results in a change in nucleotide binding to γ subunit and an allosteric change in 
AMPK. The allosteric change leads to an increase in net phosphorylation of catalytic α 
subunit at Thr-172 and subsequent AMPK activation. Activation of AMPK triggers the 
repression of ATP-consuming anabolic pathways such as synthetic pathways of fatty 
acid, triglyceride, cholesterol, glycogen and protein through the transcriptional regulation 
of gluconeogenic and lipogenic enzymes. AMPK also elicits the activation of ATP-
producing catabolic pathways by stimulating glucose uptake and glycolysis, fatty acid 
uptake and oxidation, leading to the regulation of glucose and fatty acid homeostasis 
(Fulco, 2008) (Kahn et al., 2005). As a regulator of glucose metabolism, activated AMPK 
acts via TORC2, a transcriptional coactivator of the cyclic AMP-regulated transcription 
factor, CREB, to inhibit the transcription of key gluconeogenic enzymes such as PEPCK 
and G-6-Pase (Shaw et al., 2005). As a regulator of lipid biosynthetic pathways, AMPK 
phosphorylates and inactivates ACC, resulting in a drop in concentration of the ACC 
product, malonyl CoA, an inhibitor of fatty acid entry into mitochondria for β-oxidation. 
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In other words, AMPK-caused inactivation of ACC leads to increased fatty acid 
oxidation (Hardie et al., 2012). Furthermore, AMPK also appears to decrease lipogenesis 
through downregulation of lipogenic genes, including SREBP-1 and fatty acid synthase 
(Li et al., 2011).  Chronic activation of AMPK may also induce the expression of muscle 
hexokinase and GLUT4, resulting in enhanced glucose uptake and catabolism to generate 
ATP—mimicking the effects of extensive exercise training (Zhou et al., 2001). AMPK 
also plays a role in the regulation of food intake in the hypothalamus (Shaw et al., 2011). 
As previously mentioned, AMPK is activated upon negative energy balance. But 
a higher AMP/ATP ratio is not the only way to bring about activated AMPK’s favorable 
metabolic effects. Exercise and several current anti-diabetic therapies, such as metformin, 
activate AMPK in the liver and are thought to therapeutically act in part through the 
stimulation of this pathway. Highlighting the importance of the AMPK pathway in the 
therapeutic response to metformin in humans, investigators from the Diabetes Prevention 
Program found that AMPK subunits and LKB1 genes were associated with a clinical 
response to metformin (He and Wondisford, 2015). Metformin ameliorates 
hyperglycemia without stimulating insulin secretion or causing hypoglycemia. It also has 
beneficial effects on circulating lipids linked to increased cardiovascular risk (Zhou, 
2001). Metformin is not metabolized in animals or humans and is eliminated intact 
through renal excretion. Despite the fact that metformin has been used since 1957, the 
mechanism(s) by which metformin lowers glucose and lipids remains an enigma (He and 
Wondisford, 2015). 
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Although the fact that metformin activates AMPK is well accepted (Meng 2014, 
Zang 2004, Zhou 2001), how metformin activates AMPK has remained controversial for 
years. Does metformin activate AMPK directly? If so, how? Or, does metformin 
indirectly activate AMPK via increasing the AMP/ATP or ADP/ATP ratio via inhibition 
of complex 1 of the mitochondrial respiratory chain? (He and Wondisford, 2015) 
Although many studies have confirmed that metformin’s actions are mediated through 
the activation of AMPK, some metformin effects are reported to be AMPK-independent 
such as inhibition of mTORC1 activity (Fulco, 2008). Varying results regarding how 
metformin activates AMPK could be due to differences in metformin concentrations used 
during studies. It has been suggested that lower concentrations of metformin directly 
activates AMPK, while higher concentrations inhibit the mitochondrial respiratory chain 
and indirectly activate AMPK. It has also been postulated that metformin may mediate 
AMPK activation by promoting the binding of LKB1 to AMPK (He and Wondisford, 
2015). Clearly, further research is needed to determine the molecular mechanisms 
underlying the beneficial metabolic effects of metformin. 
Sirtuin 1 (SIRT1) 
SIRT1 is one of the seven mammalian orthologs of the yeast protein Sir2, an 
NAD+-dependent protein deacetylase that extends life span. SIRT1 catalyzes a reaction 
that couples lysine deactelyation to NAD+ hydrolysis. During this reaction, NAD+ is 
hydrolyzed to nicotinamide and O-acetyl-ADP-ribose. Nicotinamide strongly inhibits 
SIRT1 deacetylase activity (Guarente, 2006, 2012). A wealth of data has shown that 
SIRT1 is a nuclear nutrient sensor that provides a molecular link between the cellular 
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energy status (via NAD+) and the adaptive transcriptional responses to nutrient status. 
Accumulated evidence demonstrates that SIRT1 levels and/or activity increase with 
nutrient deprivation and orchestrate the adaptive response to caloric restriction (Li 2013, 
Chalkiadaki 2012) 
During states of negative energy balance, the liver’s key function is to maintain 
euglycemia through glucose production via the regulation of glycogenolytic and 
gluconeogenic processes. To increase gluconeogenic capacity under fasting condition, 
SIRT1 deacetylates PGC-1α and FOXO1, thereby increasing their ability to promote the 
transcription of their gluconeogenic targets and inhibit the expression of glycolytic genes 
such as glucokinase (Rodgers et al., 2005). In addition to its role in carbohydrate 
metabolism, SIRT1 is also a key regulator of hepatic lipid homeostasis. SIRT1 
deacetylates SREBP-1 and reduces SREBP-1’s affinity to the promoters of its lipogenic 
target genes, thereby decreasing expression of lipogenic genes (Gillum, 2011). PGC-1α 
is a key coactivator for PPARα signaling. By deacetylating and activating PGC-1α and 
PPARα, SIRT1 is able to stimulate PPARα signaling and increase fatty acid oxidation. 
Taken together, SIRT1 expression and/or activity are upregulated by fasting, and it 
stimulates expression of genes involved in fatty acid oxidation and gluconeogenesis 
while downregulating expression of lipogenic genes during prolonged fasting (Schug, 
2011). 
Resveratrol (RSV) is a natural polyphenolic compound mainly found in the skin 
of grapes and is well known for its phytoestrogenic and antioxidant properties. 
Resveratrol has been shown to significantly increase SIRT1 activity through an allosteric 
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interaction as well as enhance the affinity of SIRT1 to NAD+ and deacetylate its 
substrate. By facilitating increased SIRT1 deacetylation, PGC-1α activity is induced and 
leads to increased fatty acid oxidation (Rodgers et al., 2005). SIRT1 expression is 
suppressed during insulin resistance and obesity and resveratrol treatment protects mice 
against diet-induced obesity and insulin resistance (Lagouge, 2006). Since resveratrol has 
beneficial metabolic changes—improved insulin resistance and lipid profiles, decreased 
inflammation—SIRT1-based therapies hold promise for the treatment of insulin 
resistance and type 2 diabetes (Gillum, 2011). However, there is much debate about 
whether or not the metabolic effect of resveratrol acts via direct or indirect (or both) 
activation of SIRT1. A moderate dose of resveratrol showed increased SIRT1 activity, 
mitochondrial biogenesis and function, and AMPK activation. Meanwhile, a high dose of 
resveratrol activated AMPK in a SIRT1-independent manner, demonstrating that 
resveratrol dosage is a critical factor (Price, 2012). Further studies are needed to elucidate 
whether resveratrol acts on SIRT1 to prevent metabolic disease. 
Fibroblast Growth Factor 21 (FGF21) 
The human/mouse FGF family comprises FGF1-FGF23 (Itoh 2014). Based on 
their mechanisms of action, FGFs can be classified as paracrine, intracrine, and 
endocrine. Endocrine FGFs comprise of FGF15/19, FGF21, and FGF23 and mainly 
function as hormone-like or, in part, local signaling molecules in metabolism 
(Kharitonenkov and Larsen, 2011; Kharitonenkov and Shanafelt, 2009; Kharitonenkov et 
al., 2005). Although most of paracrine and endocrine FGFs have proliferative activities, 
FGF21 is unique. FGF21 has metabolic, but not proliferative activities (Itoh 2014). 
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FGF21 is a secretory protein that is predominantly expressed in the liver and exerts 
beneficial effects on obesity and related metabolic diseases. As an endocrine hormone, 
FGF21 acts on the FGF receptor 1c (FGFR1c) with β-Klotho as a necessary cofactor. 
Both FGFR1c and β-Klotho are specifically expressed in their target tissues—liver, 
WAT, BAT, skeletal muscle, pancreas, heart, and brain (Ye et al., 2014). 
The physiological roles of FGF21 include the maintenance of energy homeostasis 
in conditions of metabolic or environmental stress. The expression of FGF21 is induced 
in multiple major metabolic organs including the liver, WAT, BAT, and skeletal muscle, 
in response to stressors—starvation, nutrient excess, exercise, and cold exposure (Kim et 
al., 2014).  Since FGF21 acts as a critical regulator in the metabolic adaptation to fasting, 
it may seem odd that FGF21 is induced in both undernutrition and overnutrition states. 
However, FGF21 signaling is impaired in the liver and WAT of obese insulin-resistant 
mice, which suggests that obesity might be a state of FGF21 resistance (Kim et al., 2014). 
Administration of exogenous FGF21 overcomes this resistance and leads to 
improvements in obesity-related metabolic deterioration. Transgenic mice overexpressing 
FGF21 exhibit resistance to diet-induced obesity and tight glycemic control (Kim et al., 
2014). Insulin resistance develops due to aberrant accumulation of intracellular lipids in 
insulin-responsive tissues, including ceramide. FGF21 diminishes the accumulation of 
ceramides in obese animals (Itoh 2014). WAT is the predominant site that confers the 
metabolic activities of FGF21. FGF21 enhances lipolysis, glucose uptake, and fatty acid 
oxidation, decreases fatty acid synthesis, and improves insulin resistance. Improved 
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metabolic parameters of obese diabetic rodents, rhesus monkeys, and human subjects 
treated with FGF21 have also been observed (Kim et al., 2014). 
FGF21 doesn’t only act as a hepatokine. Adipose tissue can also secrete FGF21 
and as an adipokine, it plays a big role in inducing thermogenesis during cold exposure or 
β-adrenergic receptor stimulation. UCP1 releases chemical energy as heat in BAT and is 
a way for excess energy to be wasted. Beige adipocytes are brown adipocyte-like cells, 
and are UCP1-positive adipocytes in WAT. Upon cold exposure, FGF21 acts in an 
autocrine/paracrine manner to activate brown adipocytes and induce the accumulation of 
beige adipocytes in WAT, thereby increasing thermogenesis and energy expenditure 
(Fisher et al., 2012). FGF21 has only recently emerged as a critical metabolic regulator 
and future studies are necessary to investigate its effects and mechanisms. Because the 
activation of pathways via AMPK, SIRT1, and FGF21 may translate into favorable 
metabolic effects, these particular nutrient sensors seem to be viable therapeutic targets. 
Goals of Thesis 
Identifying potential drug targets for modulation of metabolic diseases has 
become a high priority because consumption of calorie-dense foods coupled with a 
sedentary lifestyle has propagated obesity throughout the developed world. According to 
the Institute of Medicine, adults should get 45-65% of their daily calories from 
carbohydrates, 20-35% from fat, and 10-35% from protein. Unfortunately, the 
consumption of a high-fat, high sucrose (HFHS) diet with ~60% of calories from fat has 
become more common and has greatly contributed to the increase in the number of obese 
individuals. Globally, obesity has more than doubled since 1980 (WHO). In the U.S., 
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approximately 35% of adults are obese. An additional 34% of adults are overweight 
(CDC). This is particularly alarming because in obese individuals, excess adipose tissue 
releases increased levels of circulating free fatty acids. These excess fatty acids deposit in 
metabolic tissues such as liver, muscle, and pancreatic β-cells, resulting in non-alcoholic 
fatty liver disease (NAFLD), insulin resistance, and type 2 diabetes (Schug, 2011).  
 Metformin is the most commonly prescribed oral anti-diabetic agent worldwide 
and is taken by over 150 million of diabetic patients each year. Numerous studies in 
rodents have highlighted metformin’s ability to promote weight loss (Hu 2014, Matsui 
2010, Yasuda 2004). Furthermore, systematic reviews and meta-analyses of studies 
involving metformin have overwhelmingly demonstrated metformin’s weight loss 
capabilities in humans (Domecq, 2015). Metformin’s powerful ability to combat obesity 
and bring about weight loss has made researchers and clinicians consider the possibility 
of metformin as treatment outside diabetes. Polycystic ovary syndrome is known to be 
associated with significant weight gain. Patients with polycystic ovary syndrome were 
given lifestyle modifications to live by plus metformin, and these patients experienced 
greater weight loss than patients who only made lifestyle modifications (no metformin 
treatment) (Naderpoor et al., 2015). Despite the vast amount of evidence supporting 
metformin’s weight loss capabilities, the mechanism(s) in which metformin leads to 
weight loss remains unknown. Some studies indicate weight loss results from decreased 
caloric consumption (Matsui 2010, Yasuda 2004), while other studies report metformin 
brings upon beneficial metabolic effects without influencing food intake (Oh 2013, 
Tajima 2013). 
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 Postulating ways in which metformin reduces body weight has led researchers to 
question if metformin has effects on energy expenditure. Studies in zebrafish showed that 
insulin increases metabolic rate and that metformin, being an insulin-sensitizer, increases 
the metabolic response to insulin by 18.9% (Renquist et al. 2013). Sulphonylurea therapy 
has been reported to cause weight gain in type 2 diabetic patients. Resting metabolic rate 
of sulphonylurea-treated and metformin-treated patients was evaluated and results 
revealed both groups to have similar resting metabolic rates. However, when adjusted for 
fat free mass (lean mass), metformin-treated patients demonstrated an increased 
metabolic rate compared to sulphonyluera-treated patients (Chong et al., 1995). 
Metformin prevented olanzapine-induced weight gain in rats [olanzapine is an anti-
psychotic associated with weight gain]. But, what’s more intriguing is 
olanzapine+metformin increased UCP1 gene expression in BAT compared to olanzapine 
alone (Hu et al., 2014). Additional evidence suggests metformin increases the 
thermogenic activity of BAT: Metformin promotes VLDL-triglyceride clearance by BAT 
resulting in lower plasma triglycerides (Geerling et al., 2014).  PRDM16 is involved in 
the development and function of classical brown and beige adipocytes. PRDM16 was 
decreased in obese subjects; but, metformin treatment increased PRDM16 mRNA and 
protein levels in isolated human adipocytes and in adipose tissue (Moreno-Navarrete et 
al., 2015). Collectively, these studies suggest metformin may promote weight loss by 
increasing energy expenditure and burning of excess energy. I’m interested in 
determining if metformin can cause weight loss in HFHS diet-induced obese mice and if 
this weight loss is due to increased energy expenditure. 
	  11 
 Studies revealing metformin’s numerous effects have opened the possibility for it 
to treat other metabolic disorders other than diabetes. Metformin has recently been 
proposed to help treat non-alcoholic fatty liver disease (NAFLD) associated with obesity 
since currently, there is no treatment for NAFLD other than lifestyle modification. As of 
now, the efficacy of metformin to alleviate NAFLD is difficult to evaluate since systemic 
analyses of studies showing improved NAFLD combine metformin and lifestyle 
modifications (Mazza et al., 2012). I aim to evaluate the efficacy of metformin to 
alleviate obesity-induced NAFLD. 
 Exercise promotes weight loss, which improves NAFLD in obese individuals 
(Mazza et al., 2012). Recently, there has been much attention given to AMPK activators 
as exercise mimetics. Metformin is known to activate AMPK and similarly brings about 
many beneficial effects as exercise (Meng 2014, Zang 2004, Zhou 2001). It’s been shown 
that AMPK and SIRT1 have intertwined roles in regulating different metabolic processes. 
Numerous studies have shown that resveratrol, a known SIRT1 activator, helps prevent 
weight gain (Gillum, 2011). Transgenic mice overexpressing FGF21 exhibit resistance to 
diet-induced obesity (Kim, et al., 2014). Nutrient sensors AMPK, SIRT1, and FGF21 all 
have implications in weight loss and in the improvement of metabolic derangements. 
Since metformin activates AMPK, and AMPK and SIRT1 have intercrossing roles to 
repress lipogenesis by reducing SREBP-1 levels, I’m interested to see if SIRT1 
stimulation by resveratrol is able to mimic metformin’s amelioration of fatty. FGF21 is 
postulated to act downstream of SIRT1, therefore I’m curious to see if exogenous 
administration of FGF21 mimics stimulated SIRT1’s effect on NAFLD. 
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This thesis aims to investigate whether: 
1) metformin facilitates weight loss by increasing energy expenditure via increased 
expression of UCP1, DIO2, and PRDM16 
2) metformin is capable of alleviating NAFLD cause by HFHS diet-induced obesity 
3) SIRT1 stimulation by resveratrol and delivery of exogenous FGF21 mimics 
metformin’s ability to combat obesity and improve NAFLD 
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METHODS 
 
[Figures of experimental designs for animal studies can be found in Appendix] 
Animal Studies with Metformin Treatment 
Male C57BL6 mice matched for age were divided into three groups: one group  
(n = 7) of mice was fed a CHOW diet consisting of 18% of calories from fat, 58% from 
carbohydrates, 24% from protein (Teklad Global #2918, Madison, WI) ad libitum for 12 
weeks. The second group (n = 7) was fed a HFHS diet consisting of 59% of calories from 
fat, 26% from carbohydrates, 15% from protein (BioServ #F1850, Frenchtown, NJ) ad 
libitum for 12 weeks. The third group (n = 7) was fed a HFHS diet ad libitum for 8 
weeks, followed by 4 weeks of HFHS feeding plus metformin treatment (250 mg/kg/day) 
via drinking water. Prior to metformin administration, water intake of the metformin 
treated group was measured and the proper dosage of metformin was administered based 
on the average daily water intake. At the time of sacrifice, serum, liver, epididymal white 
adipose tissue (eWAT), inguinal white adipose tissue (iWAT), and interscapular brown 
adipose tissue (BAT) were collected. Tissues were either fixed in buffered formalin and 
processed for histology or snap frozen in liquid nitrogen and stored at -80oC until RNA 
and proteins were isolated. 
Animal Studies with Resveratrol Treatment 
Male, age-matched C57BL6 mice were divided into three groups: one group  
(n = 5) was fed CHOW ad libitum for 20 weeks. The second group (n = 5) was fed a 
HFHS diet for 20 weeks. The third group (n = 8) was fed a HFHS diet supplemented with 
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resveratrol for 20 weeks. The HFHS diet containing resveratrol provided a dose of  
130 mg/kg/day, which was calculated based on the average daily consumption of food  
(5 g/day) by a 23 g mouse. 
Animal Studies with Liver-specific SIRT1 knockout (SIRT1 LKO) Mice 
Male wild-type and SIRT1 LKO mice were age-matched and separated into four 
groups. Wild-type (n = 5) and SIRT1 LKO mice (n = 5) were fed a HFHS diet for 12 
weeks. Additional wild-type (n = 5) and SIRT1 LKO mice (n = 5) were fed a HFHS diet 
supplemented with resveratrol (130 mg/kg/day) for 12 weeks. 
Animal Studies with FGF21 Transgenic Mice 
Male wild-type and FGF21 TG on C57BL6 background were age-matched and 
separated into four groups. Wild-type (n = 5) and FGF21 TG (n = 4) were fed CHOW ad 
libitum for 12 weeks. Additional wild-type (n = 5) and FGF21 TG (n = 5) were fed a 
HFHS diet for 12 weeks. 
Animal Studies with In Vivo Adenoviral Gene Transfer 
Adenovirus-mediated overexpression of FGF21 in the liver of HFHS-fed SIRT1 
LKO mice was accomplished through intravenous injection. Two hundred microliters of 
adenovirus (5 x 109 – 1 x 1010 pfu) per mouse were injected into the tail vein using a 1mL 
syringe with a 255/8-gauge needle. Wild-type and SIRT1 LKO mice were fed a HFHS 
diet for a total of 12 weeks. At week 10 (two weeks prior to the end of feeding period), 
wild-type (n = 5) and SIRT1 LKO mice (n = 5) were injected into the tail vein with  
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Ad-GFP, and SIRT1 LKO mice (n = 8) were injected intravenously with Ad-FGF21. 
Two weeks after injection, each group of mice was sacrificed. 
Body Composition Analysis and Comprehensive Laboratory Animal Monitoring 
System (CLAMS)—Metabolic Cages 
All mice were weighed at the beginning of the HFHS diet and weekly thereafter 
until sacrificed. Body composition and CLAMS were performed in the Metabolic 
Phenotyping Core at Boston University. EchoMRI700, a non-invasive quantitative 
magnetic resonance system, determined body composition, including fat mass, lean mass, 
free water, and total body water. To acclimatize to being alone in a cage, mice going into 
the metabolic cages (CLAMS) were housed individually for one week prior to CLAMS 
experiments. CLAMS was used to measure metabolic rate, fuel utilization, and physical 
activity. Energy expenditure was assessed by indirect calorimetry measurements.  
Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT) 
GTT and ITT were performed to assess whole body glucose homeostasis and 
systemic insulin sensitivity, respectively. Blood glucose concentrations were measured 
using the AlphaTrak Blood Glucose Monitoring System for Animals.  After 16 hours of 
fasting, GTTs were performed with an intraperitoneal injection of 20% glucose solution 
(2 g/kg BW) into the mice and blood glucose levels were measured at 0, 15, 30, 60, 90, 
and 120 minutes. After 5 hours of fasting, ITTs were performed with an intraperitoneal 
injection of human insulin—Humulin R—(0.75 U/kg BW) into mice and blood glucose 
levels were measured at 0, 15, 30, 60, 90, and 120 minutes.  
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Hepatic Histology and Oil Red O Staining 
The livers from the mice were fixed for 48 hours in buffered formalin, processed, 
embedded in paraffin, cut into 5µm sections and placed on glass slides. Hematoxylin and 
eosin (H&E) staining was conducted to demonstrate general hepatic morphology.  
When animals were killed, pieces of the liver were cut and embedded in ornithine 
carbamyl transferase (OCT) and frozen over dry ice. The cryosectioner was used to cut 
the livers embedded in OCT blocks. This process was tedious and only improved with 
practice and knowledge of optimal temperature for different liver tissues. Healthy livers 
were best cut at -16 to -17oC. Fatty livers were best cut at -13oC. When the temperature 
of the crysectioner is too cold, the tissue will have lots of cracks when cut. At the same 
time, when the temperature of the cryosection is too warm, the OCT will revert back to 
its liquid form and tissue will be susceptible to degrading and will negatively affect 
cellular structures. 
Hepatic steatosis was assessed using the Oil Red O Stain from American 
MasterTech. Getting good staining results proved to be quite a difficult task. I tried out 
different protocols using different reagents like 60% propylene glycol, however the 
staining results were not good. After many times of trial and error, successful Oil Red O 
staining was achieved by exposing cryosections to 60% isopropanol for 30 seconds, 
stained with 0.3% Oil Red O in 60% isopropanol for 25 minutes, and quickly washed 
with 60% isopropanol (~30 seconds). Sections were counterstained with Harris 
Hematoxylin and mounted with aqueous solution.  
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The liver images were photographed and scanned digitally, and planimetry of Oil 
Red O positive stained areas were performed on the digitized images using NIH ImageJ 
software. Relative areas of steatosis were quantified using ImageJ and expressed as the 
percentage of area stained with Oil Red O. 
Adipose Histology 
Pieces of iWAT and BAT of mice were fixed for 48 hours in buffered formalin, 
processed, embedded in paraffin, cut into 7µm sections and placed on glass slides. H&E 
staining was conducted to demonstrate general adipose morphology. 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Interscapular BAT and inguinal WAT were collected from mice. RNA was 
extracted using the RNeasy Lipid Tissue Mini Kit (QIAGEN), and cDNA was generated 
with the QuantiTect Reverse Transcription Kit (QIAGEN) according to the 
manufacturer’s instructions. First-strand cDNA was generated by reverse-transcription 
using total RNA. RT-PCR was performed using the ViiA TM7 Real Time PCR System 
with the SYBR Green Real Time PCR Master Mixes (Applied Biosystems) according to 
the manufacturer’s instructions. The relative levels of mRNA were determined using the 
ΔΔCT Method, normalizing to GAPDH, and expressed as relative mRNA levels.  
Statistical Analysis 
Data are expressed as means ± SEM. The significance of the differences in the 
mean values was evaluated by using ANOVA, ANCOVA, or 2-tailed Student’s t test. 
Values of P < 0.05 were considered to be statistically significant. 
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RESULTS 
 
Metformin Improves Fatty Liver and Restores Glucose Tolerance and Glucose 
Homeostasis in Diet-induced Obese Mice 
Overnutrition-induced obesity is associated with the development of NAFLD. 
Compared to CHOW-fed mice, HFHS-fed mice exhibited severe hepatic steatosis. 
Metformin treated HFHS-fed mice displayed significant reductions in steatosis compared 
to HFHS-fed mice, as demonstrated by a ~60% reduction in Oil Red O-stained areas  
(Fig. 1).  
To determine the effect of metformin on systemic glucose homeostasis, 
intraperitoneal GTT was performed. Metformin treated HFHS-fed mice displayed an 
                                       
    
Figure 1. Metformin alleviates hepatic 
lipid accumulation in HFHS-fed mice. 
A. 20X  B. 40X  C. ORO positive % area 
* P < 0.05 vs. CHOW,  
# P < 0.05 vs. HFHS 	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~34% reduction in fasting glucose levels, compared with those of HFHS-fed mice  
(105.9 ± 4.07 vs. 161.0 ± 4.08 mg/dl). In fact, such lowered glucose levels in metformin-
treated mice were comparable to those of normal control mice (Fig. 2). Consistently, 
integrated blood glucose concentrations, as calculated by the area under the curve (AUC), 
were significantly decreased by ~40% in metformin-treated mice (Fig. 2). 
 
Metformin Decreases Adiposity and Improves Body Composition in HFHS-fed Mice 
Metformin treatment effectively caused body weight loss (Fig. 3A). Other studies 
have report that metformin suppresses food consumption in mice (Matsui 2010, Yasuda 
2004). While housed individually for a week to acclimatize mice for being alone in 
metabolic cages, food intake of all mice in the study was recorded to help determine 
whether the weight loss of the metformin-treated mice was due to metformin’s ability to 
constrain hyperphagia (thus decrease calorie intake). Food intake measurements show 
     
Figure 2. Metformin improves glucose clearance in HFHS-fed mice. GTTs were 
performed on mice following a 16 hour fast. Data presented as means ± SEM (n = 7). 
* P < 0.05 vs. CHOW, # P < 0.05 vs. HFHS 
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that metformin-treated HFHS-fed mice consumed fewer calories daily compared to 
CHOW-fed and HFHS-fed mice (Fig. 3C). It’s possible that this decreased caloric 
ingestion could be responsible for the decreased body weight of the metformin-treated 
mice (Fig. 3B). HFHS-induced obese mice had increased adipose tissue mass, both in 
   
 
 
                  
 
  
 
Figure 3. Metformin treatment 
promotes weight loss, reduces food 
intake, and improves body 
composition in HFHS-fed mice. 
A. Body weight change over treatment 
period B. Final body weight C. Food 
intake D. Fat and lean mass E. Percent 
fat and lean mass 
Data presented as means ± SEM (n = 7).  
* P < 0.05 vs. CHOW,  
# P < 0.05 vs. HFHS 
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terms of absolute fat mass and fat weight to body weight ratio. Along with lower body 
weight, metformin-treated mice had decreased fat mass, lower percent body fat, and 
higher percent lean mass compared to their HFHS-fed counterparts (Fig. 3D-E). Thus, 
metformin promotes weight loss and fat mass reduction. 
To elucidate the physiological mechanism underlying metformin action on fat 
tissue, H&E staining and IHC analysis of inguinal white adipose tissue (iWAT) and 
brown adipose tissue (BAT) were performed. Multiple slides with H&E staining of 
iWAT sections showed enlarged adipocytes as well as the development of crown-like 
structures in diet-induced obese mice, compared to CHOW-fed mice. Looking at stained 
H&E slides, metformin treatment appears to reduce adipocyte size as well as exhibit 
normal cellular structures (Fig. 4A). To ensure the conclusion that metformin reduces 
adipocyte size is valid, adipocyte cell volume of HFHS-fed and HFHS+Metformin-fed 
mice needs be quantified and analyzed in the future. Metformin-treated mice did not 
exhibit enlarged unilocular lipid droplets in the BAT, which were observed in the BAT of 
mice after HFHS feeding (Fig. 4B). Interestingly, metformin-treated ob/ob mice 
exhibited adipocytes expressing the key thermogenic gene, UCP1, indicating the presence 
of beige adipocytes in iWAT (Fig. 4C). Metformin might play a role in the regulation of 
adipose tissue functions during obesity. 
Metformin Induces the Expression of Thermogenic Genes and Promotes Browning of 
iWAT by Inducing PRDM16 Expression 
Since subcutaneous iWAT is particularly prone to inducing a thermogenic gene 
program (browning), we characterized the effects of metformin on fat tissue function. 
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Gene expression of UCP1 was enriched in iWAT of metformin-treated mice (Fig. 5A), 
consistent with the presence of beige adipocytes in these pads. Expression of DIO2, 
another thermogenic gene, was also upregulated in the iWAT of mice treated with 
metformin (Fig. 5B). PRDM16 is involved in the development and function of classical 
brown and beige adipocytes. To determine whether metformin might be involved in the 
remodeling of white adipose tissues, mRNA levels in subcutaneous iWAT were assessed. 
PRDM16 was significantly elevated in the iWAT of metformin-treated mice relative to 
the very low levels of expression in iWAT of HFHS-fed mice (Fig. 5C). 
Metformin Does Not Seem to Increase Energy Expenditure in HFHS-fed mice 
Since metformin promoted whole body weight loss, decreased lipid accumulation 
in both liver and white adipose tissues, and increased expression of thermogenic genes in 
iWAT, metformin’s effects on energy expenditure was also investigated. When each 
mouse was plotted, energy expenditure increased as body weight increased (Fig. 6A). 
Energy expenditure also increases proportionally to lean mass (Fig. 6B). ANCOVA 
statistical analysis was done to investigate whether HFHS-fed mice and 
HFHS+Metformin-fed mice had any differences in energy expenditure that was higher 
than expected based on their body weight or lean mass. Unadjusted energy expenditure 
(average over 24h) means for HFHS and HFHS+Metformin were 0.700 and 0.568 kcal/hr 
per mouse, respectively. The metformin-treated group weighed ~20g less than HFHS-fed 
mice (Fig. 3B). After adjusting energy intake for body weight, the energy expenditure 
was similar: HFHS (0.62 kcal/hr) and HFHS+Metformin (0.64 kcal/hr), N.S, P = 0.43. 
ANCOVA analysis resulted in an aggregate correlation within samples of r2 = 0.83,  
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Figure 5. Metformin increases expression of thermogenic genes such as UCP1 (A) 
and DIO2 (B) as well as the co-regulatory protein PRDM16 (C) in subcutaneous 
inguinal white adipose tissue of HFHS-fed mice.  
Thermogenic gene expression normalized to CHOW-fed mice. (n = 5-7)  
# P-value < 0.05 vs. CHOW 
 
 
 
 
 
  
Figure 4. Metformin 
reduces adiposity in 
iWAT of diet-induced 
obese mice and increases 
UCP1 expression in 
iWAT of obese mice. 
Representative H&E 
staining of A. iWAT and 
B. BAT in mice fed a 
CHOW, HFHS, and 
HFHS+Metformin diet. 
C. Metformin increases 
UCP1 expression in iWAT 
of ob/ob mice. 	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meaning HFHS feeding, metformin, and body weight together explains 83% of the 
variability in energy expenditure. When energy expenditure was adjusted for lean mass, 
ANCOVA analysis revealed that the adjusted means were slightly higher in the HFHS 
(0.67 kcal/hr) than the HFHS+Metformin (0.6 kcal/hr) group (P = 0.03). Aggregate 
correlation within samples was r2 = 0.48, meaning HFHS feeding, metformin, and lean 
mass together explains 48% of the variability in energy expenditure. The fact that body 
weight better predicts energy expenditure than lean mass implies that fat mass only 
contributes to total energy expenditure. 
  
Graphs depicting physical activity of the three groups (Fig. 7B-D) shows that 
physical activity was similar between the three groups and that weight loss observed in 
metformin-treated mice is not due to increased physical activity. Consistent with what is 
already known about mice, physical activity graphs show that mice are more active 
during the hours of 7pm and 7am (dark cycle). 
 
 
Figure 6. Energy expenditure is proportional to body weight.  
A-B. Data depicted in terms of means per mouse. 
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RER measurements resulted in the following means: CHOW (0.922), HFHS 
(0.795), and HFHS+Metformin (0.783). ANOVA analysis of RER revealed no significant 
difference in fuel utilization (fat vs. carbohydrate) between HFHS-fed and 
HFHS+Metformin-fed mice but both were significantly different from the higher RER 
observed in CHOW-fed mice, as expected because CHOW is higher in carbohydrate  
(P = 0.01) (Fig. 7A).  
 
    
 
      
 
Figure 7. Fuel utilization and physical activity of CHOW, HFHS, and 
HFHS+Metformin mice. A-D. Data depicted in terms of means per group. 
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Resveratrol Attenuates Diet-induced Obesity in Mice While Improving Fasting Blood 
Glucose Levels 
Overnutrition leads to obesity and along with obesity is insulin resistance. This is 
evident in the increased body weight and increased fasting blood glucose levels of the 
HFHS-fed group. Mice treated with resveratrol had a modest decrease in total body 
weight (Fig. 8A). Interestingly, resveratrol lowered fasting blood glucose levels nearly to 
normal levels (Fig. 8B). 
Resveratrol Stimulates Hepatic AMPK and Alleviates Fatty Liver in Obese Mice 
AMPK also exerts effects on lipid metabolism, largely via ACC. Activated 
AMPK triggers phosphorylation of ACC, which in turn deactivates ACC and fatty acid 
synthesis while promoting fatty acid oxidation (Li et al., 2011). To investigate the role of 
resveratrol and activated SIRT1 on AMPK activity and AMPK’s downstream targets 
(specifically ACC), mice were fed CHOW, HFHS, or HFHS+RSV (130mg/kg/day) for 
20 weeks. Consistent with our previous studies (Li et al., 2011), phosphorylation of  
 
 
Figure 8. Resveratrol reduces impact of diet-induced obesity and improves the 
fasting blood glucose of HFHS-fed mice. A. Body weight B. Fasting blood glucose 
(md/dL). Data presented as means ± SEM (n = 5-8). * P-value < 0.05 vs. CHOW,  
# P-value < 0.05 vs. HFHS 
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AMPK at the Thr-172 site and consequently phosphorylated ACC were decreased in 
HFHS-fed mice (Fig. 9A-B). Increased hepatic lipid accumulation was evidenced by 
	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	   	  
Figure 9. Resveratrol prevents the inhibition of hepatic AMPK in HFHS diet-
induced obese mice. A. Hepatic AMPK and ACC activity as measured by the amount 
of pAMPK and pACC, respectively B. Bar graphs showing pAMPK and pACC levels  
* P < 0.05 compared to CHOW,  # P < 0.05 compared to HFHS 
 
 
  
Figure 10. Resveratrol 
improves hepatic steatosis 
in HFHS diet-induced 
obese mice.  
A. 20X   B. 40X  
C. ORO positive % area   
* P < 0.05 compared to 
CHOW, # P < 0.05 
compared to HFHS 	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increased positive Oil Red O-staining (Fig. 10A-C). Consistent with increased AMPK 
activity, hepatic steatosis was attenuated by resveratrol (Fig. 10A-C). 
Resveratrol-Treatment Enhances Insulin Signaling in the Liver of HFHS-fed Mice 
Insulin acts via phosphorylation regulation of Insulin Receptor Substrate 1 (IRS1) 
and Akt, aka Protein Kinase B (Gual, 2005). Since resveratrol increased hepatic AMPK 
signaling, it was postulated that impaired insulin signaling of HFHS-fed mice would also 
be attenuated by resveratrol. Compared to the HFHS-fed mice, the resveratrol-treatment 
decreased IRS1 serum phosphorylation and increased Akt phosphorylation in the liver 
(Fig. 11), which is indicative of enhanced hepatic insulin signaling. 
 
 
 
Figure 11. Resveratrol enhances insulin sensitivity in the liver of diet-induced 
obese mice. A-B. Protein expression of hepatic phosphorylation of Akt and IRS1  
B-C. Bar graphs show changes in phosphorylated Akt and phosphorylated IRS1 
* P-value < 0.05 compared to CHOW, # P-value < 0.05 compared to HFHS 
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Resveratrol Stimulates Hepatic AMPK Activity and Alleviates Fatty Liver in HFHS 
Diet-induced Obese Mice through SIRT1 
 
The functional importance of SIRT1 for resveratrol metabolic action has not been 
examined. To investigate whether resveratrol stimulates of AMPK through SIRT1, wild 
type and SIRT1 LKO mice were fed either a HFHS or HFHS+RSV (130mg/kg/day) diet 
for 12 weeks. HFHS-fed SIRT1 LKO mice have pronounced weight gain compared to 
HFHS-fed wildtype (Fig. 12A-B). Food intake measurements were done to assess if this 
difference in body weight is due to differences in caloric consumption. However, food 
                            
  
 
Figure 12. The effect of pharmacological SIRT1 activator, resveratrol, on body 
weight and food intake.  A. Body weight gain B. Final body weight. C. Food intake 
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intake was not significantly different among the four groups (Fig. 12C). When fed a 
HFHS diet, SIRT1 LKO mice demonstrate decreased p-AMPK and p-ACC compared to 
wild-type mice (Fig. 13). SIRT1 LKO’s decrease in AMPK activity and increase in ACC 
activity coincides with SIRT1 LKO’s worsened hepatic steatosis when compared to wild-
type (Fig. 14). Together, these results suggest that SIRT1 helps reduce the impact of 
HFHS diet-induced obesity on the fatty liver of mice. 
 
Resveratrol treatment increased phosphorylation of AMPK and in turn, increased 
phosphorylation of ACC in wild type mice fed on the HFHS diet (Fig. 13). In line with 
this, resveratrol-induced increase in AMPK activity was associated with improved 
hepatic steatosis in these mice, as reflected by decreased Oil Red O stained areas  
(Fig. 14). However, the ability of resveratrol to simulate AMPK and reduce fatty liver 
 
 
Figure 13. Resveratrol 
stimulates hepatic AMPK 
activation in a SIRT1-
dependent manner.  
A. Protein expression of 
phosphorylated AMPK & ACC  
B-C. Bar graphs shows changes 
in AMPK and ACC 
phosphorylation.  
* P < 0.05 vs. WT HFHS,  
# P < 0.05 vs. WT HFHS+RSV	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was diminished in SIRT1 LKO mice. This indicates that SIRT1 is at least partially 
necessary for the beneficial effect of resveratrol on obesity-induced fatty liver. 
Overexpression of FGF21 in Mice Mimics Resveratrol’s Ability to Improve Fatty Liver 
 
                
 
Figure 14. Resveratrol alleviates fatty 
liver through SIRT1.  
A. 20X  B. 40X  C. ORO positive % area 
* P < 0.05 vs. HFHS-fed wild-type mice,  
# P < 0.05 vs. resveratrol treated  
wild-type mice 
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As shown above, resveratrol, a SIRT1 activator, alleviates HFHS diet-induced 
obesity and fatty liver disease. Recent studies implicate FGF21 in the regulation of body 
weight and lipid metabolism (Coskun 2008, Xu 2009). To test the hypothesis that FGF21 
functions downstream from SIRT1 as a modulator of obesity- induced NAFLD and 
insulin resistance, wild type and FGF21 transgenic mice were fed either a CHOW or 
HFHS diet for 12 weeks. 
 
 
Figure 15. FGF21 transgenic mice have decreased total body weight and 
improved glucose tolerance when fed a CHOW-diet. 
A. Body weight  B. Fat and lean mass  C. Percent fat and lean mass   
D. GTTs were performed following a 16 h fast. E) AUC for GTT  
Data presented as means ± SEM (n = 4-5). * P < 0.05 vs. WT group   
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Figure 16. FGF21 transgenic (FGF21 TG) mice are resistant to HFHS diet-
induced obesity, as demonstrated by reduced fat mass, improved glucose 
tolerance, and insulin sensitivity. 
GTTs were performed following a 16-hour fast. ITTs were performed after a 5-hour 
fast. Data presented as means +- SEM (n = 5 per group). * P < 0.05 vs. WT mice 
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When fed a CHOW diet, FGF21 transgenic mice have a lower total body weight 
but their percent body fat and percent lean mass are similar to that of wild-type mice  
(Fig. 15A-C). Intraperitoneal GTTs demonstrated that CHOW-fed FGF21 transgenic 
mice had slightly improved glucose tolerance (Fig. 15D-E). Interestingly, HFHS feeding 
revealed major differences between the two genotypes. FGF21 transgenic mice were 
resistant to diet-induced obesity and insulin resistance, and remained lean throughout the 
whole 12 week HFHS feeding. Body composition measurements revealed that FGF21 
transgenic mice have a dramatically decreased fat mass with a significantly reduced 
percent body fat (Fig. 16A-C). 
Intraperitoneal GTTs showed that HFHS-fed FGF21 transgenic mice have 
significantly lower glucose levels and improved glucose tolerance, compared to  
HFHS-fed wild-type mice (Fig. 16D). Consistently, the AUC for GTT was significantly 
decreased in mice overexpressing FGF21 in the liver (Fig. 16E). FGF21 transgenic mice  
     
 
Figure 17. FGF21 transgenic mice are resistant to HFHS diet-induced fatty liver. 
A. 20X   B. ORO positive % area      * P-value < 0.05 compared to wild-type CHOW,  
# P-value < 0.05 compared to wild-type HFHS  
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have a significantly lower AUC for ITT compared to HFHS-fed wild-type, showing 
evidence for improved insulin resistance in FGF21 transgenic mice (Fig. 16F-G).  
In line with improved glucose tolerance and insulin resistance, FGF21 transgenic 
mice have alleviated hepatic steatosis despite being on a HFHS diet. There is a dramatic 
reduction in Oil Red O-stained areas in FGF21 transgenic mice (Fig. 17). 
FGF21 Rescues the Increased Susceptibility to Weight Gain and Fatty Liver of 
Hepatocyte-Specific Deletion of SIRT1 in Mice 
The HFHS diet-induced obesity of the SIRT1LKO mouse model is characterized 
by increased fat mass, insulin resistance, and hepatic steatosis even worse than its wild 
 
 
Figure 18. Adenovirus-mediated 
overexpression of FGF21 in the liver 
reduces body weight and fat mass in 
SIRT1 LKO mice fed a HFHS diet.  
A. Body weight    B. Fat and lean mass   
C. Percent fat and lean mass 
Data presented as means ± SEM (n=5-7) 
* P-value < 0.05 compared to WT+Ad-GFP,  
# P-value < 0.05 compared to  
SIRT1 LKO+Ad-GFP 
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type counterparts. FGF21 has emerged as important regulator of body weight and given 
that fatty liver is associated with FGF21 insufficiency in SIRT1 LKO mice (Li 2014, 
Kahn 2005), rescue experiments with adenovirus encoding FGF21 (Ad-FGF21) were 
performed to determine the effect of FGF21 gain-of-function on the body weight and 
steatotic phenotype of SIRT1 LKO mice. 
Ad-FGF21 injected SIRT1 LKO mice had a modest weight loss resulting in a 
final body weight similar to wild-type Ad-GFP injected mice (Fig. 18A). Besides 
improvement in whole body weight, SIRT1 LKO mice injected with Ad-FGF21 exhibited 
improvements on body composition. Ad-FGF21-injected mice had decreased percent fat 
 
 
Figure 19. FGF21 improves hepatic steatosis 
in SIRT1 LKO mice on a HFHS diet.  
A. 20X    B. 40X   C. ORO positive % area 
* P < 0.05 compared to WT+Ad-GFP,  
# P < 0.05 compared to SIRT1 LKO+Ad-GFP 
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mass (Fig. 18C). Fatty liver in SIRT1LKO mice was attenuated by FGF21 
overexpression, as reflected by a reduction in Oil Red O-stained areas (Fig. 19). 
Overexpression of FGF21 in the Liver Ameliorates Glucose Tolerance and Restores 
Glucose Homeostasis in SIRT1 LKO Mice Fed a HFHS Diet 
To determine in vivo function of hepatic FGF21 gain-of-function on glucose 
homeostasis and insulin sensitivity, GTT and ITT were performed on the HFHS-fed 
SIRT1 LKO mice that were injected with either the GFP or FGF21 adenovirus. Two 
weeks after the injection of the adenovirus, SIRT1LKO mice expressing FGF21 
displayed a ~13% reduction in fasting glucose levels, compared with those of Ad-GFP-
injected SIRT1LKO mice (130.3 + 8.9 vs. 167.0 + 11.7 mg/dl) (Fig. 20).  
 
In intraperitoneal GTTs, SIRT1 LKO mice expressing FGF21 showed 
significantly lower glucose levels and improved glucose tolerance, compared to Ad-GFP-
injected SIRT1 LKO mice (Fig. 21A). Consistently, integrated glucose concentrations 
calculated as AUC were significantly decreased in SIRT1LKO mice expressing FGF21 
(Fig. 21B). In intraperitoneal ITTs, SIRT1LKO mice expressing FGF21 showed 
 
 
 
 
 
 
Figure 20. Overexpression of hepatic 
FGF21 lowers fasting blood glucose 
levels. Data presented as means ± SEM  
(n = 5-7). * P < 0.05 vs. WT+Ad-GFP,  
# P < 0.05 vs. SIRT1 LKO+Ad-GFP 	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significantly lower insulin levels and improved insulin sensitivity, compared to 
SIRT1LKO mice expressing control GFP (Fig. 21C). Consistently, integrated insulin 
concentrations calculared as AUC was significantly decreased in SIRT1 LKO mice 
expressing FGF21 (Fig. 21D). These results demonstrate that the defective metabolic 
phenotype of HFHS-fed SIRT1LKO mice is partially reversed by FGF21. 
 
 
 
Figure 21. Adenovirus-mediated overexpression of FGF21 in the liver restores 
glucose metabolism and protects against insulin resistance in HFHS diet-induced 
obese SIRT1 LKO mice. 
A) GTTs were performed on mice fasted for 16 h  B) AUC for GTT  C) ITTs were 
performed on mice fasted for 5 h  D) AUC for ITT     Data presented as means ± SEM  
(n = 5-7). * P < 0.05 vs. WT+Ad-GFP,  # P < 0.05 vs. SIRT1 LKO+Ad-GFP 
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DISCUSSION 
 
This thesis intended to investigate if metformin’s weight loss capability is due to 
increased energy expenditure via increased expression of UCP1, DIO2, and PRDM16. 
Additionally, I aimed to evaluate metformin’s efficacy in alleviating NAFLD cause by 
HFHS diet-induced obesity and if SIRT1 stimulation by resveratrol and delivery of 
exogenous FGF21 mimics metformin’s ability to combat obesity and improve NAFLD. 
Metformin treatment in diet-induced obese mice caused weight loss and improved 
body composition. In line with this, systematic reviews and meta-analyses of studies 
involving metformin have overwhelmingly demonstrated metformin’s weight loss 
capabilities in humans (Domecq, 2015). The weight loss and decreased fat mass seen in 
metformin-treated HFHS-fed mice may be due to the slight decrease in food intake  
(Fig. 3C). Other studies have reported that metformin decreases food consumption in 
mice (Matsui 2010, Yasuda 2004). Studies looking into the effect of metformin on energy 
intake and satiety in obese children also show that metformin decreased caloric 
consumption and lead to significant weight loss (Adeyemo, 2015). For future studies, it 
may be a good idea to pair-feed the HFHS+Metformin group with the HFHS group so 
that both groups have the same caloric intake. With both groups consuming the same 
amount of calories, it would be easier to determine whether the differences in body 
weight was due to metformin’s ability to reduce food intake or via another mechanism. 
Because metformin promotes weight loss and fat mass reduction, we were curious 
whether metformin plays a role in the regulation of thermogenesis during obesity. 
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Metformin was found to induce the expression of thermogenic genes, UCP1 and DIO2, 
and promote browning of iWAT by inducing PRDM16 expression. It was hypothesized 
that metformin increases whole body energy expenditure and via increased 
thermogenesis, metformin is able to foster weight loss and improved body composition. 
Adjusted energy expenditure means: HFHS (0.62 kcal/hr) and HFHS+Metformin  
(0.64 kcal/hr) turned out to be contrary to my hypothesis. If one simply looks at the 
unadjusted means of HFHS (0.700 kcal/hr) and HFHS+Metformin (0.568 kcal/hr) and is 
not careful, one could misinterpret results. HFHS+Metformin-fed mice do have lower 
energy expenditure but this is due to their smaller body weight compared to the HFHS-
fed mice, not due to metformin. HFHS-fed mice have higher energy expenditure due their 
increased weight (both increased fat mass and increased lean mass to be able to hull 
around the increased fat mass). 
Similar misinterpretations regarding energy expenditure can occur when data is 
expressed as kcal/kg/hr instead of the correct way—kcal/hr/mouse. One cannot simply 
divide energy expenditure by kg of body weight because HFHS-fed mice have higher 
body weights and thus would be divided by a larger number. Doing this would result in 
the misinterpretation that HFHS-fed mice have decreased energy expenditure. This is a 
concern because most of this excess weight is composed of fat, which does not have a 
high metabolic rate. Likewise, energy expenditure of HFHS+Metformin-fed mice would 
be divided by a smaller number (their kg of body weight is lower and less of it is fat) and 
this would result in the misinterpretation that HFHS+Metformin mice have increased 
energy expenditure compared to HFHS-fed mice (Tschop 2011). To correctly analyze 
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energy expenditure, one must use the data as kcal/hr/mouse, and then use ANCOVA 
statistical analysis to adjust for body weight or lean mass. Analyses can also enter fat 
mass, which requires energy to move, and this should be done in future analyses of this 
data. It would also be important to separately analyze day and night values, because mice 
are more active at night, when they also eat. 
When energy expenditure was adjusted for lean mass, ANCOVA analysis resulted 
in the following adjusted means: HFHS (0.67 kcal/hr) and HFHS+Metformin  
(0.6 kcal/hr). These results indicate that when adjusted for lean mass, metformin-treated 
mice have an 11% decrease in energy expenditure. This was opposite of what we 
postulated. However, these energy expenditure measurements were taken while the 
metformin-treated mice were still losing weight and in a state of negative energy balance. 
Associated with being in a state of negative energy balance is decreased energy 
expenditure, which could explain the results above. It’s quite probable that a metformin 
effect on energy expenditure could have been masked. What should have been done/what 
should be done in a future study is wait to get energy expenditure measurements once the 
weight loss of the metformin-treated group has plateaued and are no longer in a state of 
negative energy balance. Supporting the need for future investigation, aggregate 
correlation within samples when adjusted for lean mass was r2 = 0.48. This means HFHS 
feeding, metformin, and lean mass together explain 48% of the variability in energy 
expenditure, leaving over half of variability unexplained. Further considerable research is 
necessary to determine whether the unexplained variability can be explained if energy 
expenditure of HFHS+Metformin-fed mice is measured at a more appropriate time. 
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Evidence that the search for metformin’s effect on energy expenditure shouldn’t 
be abandoned, metformin-induced inhibition of the mitochondrial respiratory chain 
increases FGF21 expression, thereby increasing activation of brown adipocytes and 
promoting browning of iWAT (Kim Lee 2013). Resveratrol has also recently been shown 
to induce browning of iWAT via AMPK activation (Wang 2015). It would be interesting 
to investigate how resveratrol and delivery of exogenous FGF21 affects energy 
expenditure. 
Oil Red O staining and GTTs demonstrate metformin’s ability to alleviate 
NAFLD and restore glucose homeostasis in HFHS diet-induced obese mice. Performing 
ITTs would help delineate whether or not metformin improves insulin sensitivity and to 
gain more knowledge, this should be done in the future. Resveratrol stimulation of SIRT1 
attenuated weight gain and was able to sustain healthy fasting blood glucose levels in 
mice (Fig. 8). Consistent with other studies (Lagouge 2006), our studies indicate that 
resveratrol protects against diet-induced obesity and hyperglycemia. Furthermore, our 
studies determined that SIRT1 is at least partially needed for resveratrol to carry out its 
metabolic benefits. 
It’s been shown that AMPK and SIRT1 have multiple and intercrossing roles in 
regulating different metabolic processes. SIRT1 can activate AMPK, likely via directly 
deacetylating the AMPK protein kinase, LKB1, increasing the phosphorylation and 
activity of AMPK (Hou et al., 2008; Lan et al., 2008). SIRT1 and AMPK may be part of 
an autoregulatory loop where activation of AMPK somehow increases cellular 
NAD+/NADH ratio, in turn activating SIRT1. SIRT1 and AMPK do not function 
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independently or linearly and considerable research efforts are still needed to better 
understand the intertwined roles of AMPK and SIRT1 (Price 2012). Resveratrol has been 
described to stimulate SIRT1 and repress lipogenesis. Highlighting the intertwined roles 
of AMPK and SIRT1, resveratrol increased AMPK’s activity, which suppressed fatty 
acid synthesis by phosphorylating and inactivating ACC. Resveratrol’s ability to promote 
fatty acid oxidation may explain its attenuation in hepatic steatosis (Fig. 9C-E).  
SIRT1 LKO mice are more susceptible to obesity-induced NAFLD and the 
defective AMPK activity may explain profound fatty liver in obese SIRT1 LKO mice 
(Fig. 13). Further demonstrating the importance of SIRT1, metformin action is impaired 
in cells lacking SIRT1 (Canto 2009). Fatty liver is associated with FGF21 insufficiency 
in SIRT1 LKO mice (Li et al., 2014). Ablation of SIRT1 in the liver increases the 
propensity for weight gain and hepatic steatosis; but intriguingly, this can be rescued via 
adenoviral overexpression of FGF21. Furthermore, GTTs and ITTs showed that 
exogenous FGF21 delivery can reverse defective glucose homeostasis and improve 
insulin sensitivity.  
Evaluation of Diets Used in Animal Studies 
The CHOW diet used in these experiments is the 2918 Irradiated Teklad Global 
18% Protein Rodent Diet from Harlan Laboratories. This CHOW is comprised of 24% of 
calories from protein, 18% from fat, and 58% from carbohydrates. The IOM recommends 
adults to get 10-35% of their calories from protein, 20-35% from fat, and 45-65% from 
carbohydrates. CHOW could be considered “low fat” seeing that its fat content is slightly 
lower than IOM recommendations. CHOW has an energy density of 3.1 kcal/gram. 
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CHOW’s source of protein is soybean meal and its source of fat is soybean oil. CHOW’s 
source of carbohydrate is ground wheat, ground corn, and wheat midds. The HFHS diet 
used in these experiments is the F1850 High fat mouse diet paste from BioServ. This 
HFHS diet is comprised of 15% of calories from protein, 59% from fat, and 26% from 
carbohydrates. The HFHS diet is 5.51 kcal/gram. The source of protein for this diet is 
casein and its source of fat is lard. This HFHS diet’s source of carbohydrate is 
maltodextrin. 
Harlan Laboratories’ CHOW and BioServ’s HFHS diet have completely different 
sources of protein, fat, and carbohydrate. If one chooses to use these two diets in an 
experiment to compare low fat and high fat diets, the different sources of protein, fat, and 
carbohydrate can lead to confounding results. For instance, CHOW’s source of fat is 
soybean oil while the source of fat for the HFHS diet is lard. It has been shown that 
replacing lard with soybean oil in high-fat diet alleviates obesity-related inflammation 
and insulin resistance (Wang, Yang 2013). The difference in the source of fat would 
corrupt the results gathered from that study. This CHOW would not be a good control 
diet for this HFHS diet. Appropriate control diets should have the same source of protein, 
fat, and carbohydrate.  
Since our studies evaluated metformin and resveratrol treatment in HFHS-fed 
mice we avoided the problem of having an improper control diet. However, the HFHS 
diet from BioServ used in all our studies does not contain fiber. Fiber helps regulate the 
body’s use of sugars, helping keep hunger and blood sugar in check. High fiber intake 
has been linked to a lower risk of type 2 diabetes and heart disease. It’s possible that this 
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lack in fiber confounded some of our results or contributed to variation in our results. It’s 
also important to mention that this HFHS diet is comprised of 60% of calories from fat, 
which is quite high. Although it’s true that Western societies typically consume diets high 
in fat, 60% is not representative of a typical high-fat diet in humans. 
Conclusion 
Overnutrition from consumption of diets high in fat and sugar has propagated the 
incidence of obesity. Excess adipose tissue of obese individuals releases increased levels 
of circulating free fatty acids and these excess fatty acids overload metabolic tissues such 
as liver, muscle, and pancreatic β-cells, resulting in NAFLD, insulin resistance, and type 
2 diabetes. Metformin, the most commonly prescribed anti-diabetic drug, facilitates 
weight loss likely via decreasing caloric intake. Metformin increased expression of 
UCP1, DIO2, and PRDM16; but did not seem to increase energy expenditure. However, 
energy expenditure was measured during a state of negative energy balance, which may 
have masked an effect of metformin on metabolic rate. Further studies are needed to 
determine whether metformin-mediated increased expression of thermogenic genes 
translates into increased whole body energy expenditure. Our studies demonstrate that 
metformin is capable of alleviating NAFLD caused by HFHS diet-induced obesity and 
that SIRT1 stimulation by resveratrol and exogenous administration of FGF21 mimics 
metformin’s ability to combat obesity and improve hepatic steatosis. Collectively, these 
results implicate metformin, resveratrol, and exogenous administration of FGF21 as 
beneficial therapies for weight loss and amelioration of NAFLD. 
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Figure 22.  A proposed working model for the mechanisms through which AMPK, 
SIRT1, and FGF21 modulate the progression of obesity, NAFLD, and insulin 
resistance. 
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APPENDIX 
	  
  
 
 
 
 
 
 
 
 
 
 
 
 
Experimental design of animal studies with metformin treatment. 
 
Experimental design of animal studies with resveratrol treatment. 
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Experimental design of wild-type and SIRT1 LKO mice with resveratrol treatment. 
 
. 
 
Experimental design of wild-type and FGF21 transgenic mice fed CHOW and a 
HFHS diet. 
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